Consistent with the previous literature (Le et al., 2022; Wongvibulsin et al., 2022), our analysis also found that patients receiving anti-CTLA-4 monotherapy were less likely to develop the selected cutaneous adverse events compared to PD-1 monotherapy, such as vitiligo, PPE, and SJS/TEN. Here, CTLA4 is linked to vitiligo.